Eli Lilly & Co. vs Repligen Corp
LLY vs RGEN — side-by-side comparison from reported financials. LLY leads 9, RGEN leads 1 of 10 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Repligen Corp
RGEN · Healthcare
$173.88+6.13%Mixed
| Metric | LLY | RGEN |
|---|---|---|
| Price | $1 177.20 | $173.88 |
| Market cap | $1.05T | $11.0B |
| Revenue (TTM) | $79.7B | $785M |
| Revenue growth | +31.7% | -2.7% |
| Net margin | 33.5% | 5.3% |
| Free cash flow | $18.2B | $112M |
| Net cash (debt) | ($35.2B) | $225M |
| 1-year price return | +37.6% | +16.8% |
| P/E | 41.6 | 265.8 |
| P/E vs own history (cheap-side %) | 88% | 2% |
| Dividend yield | 0.52% | — |
| Return on equity | 93% | 2% |
| Altman Z-score | 7.10 | — |
| CV checks passed | 11 of 11 | 7 of 11 |
| Employees | 50,000 | 2,000 |
Full résumé-style profiles: LLY CV · RGEN CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.